CD274 and non-small cell lung carcinoma: The PD‐L1 TPS cutoff values of 20% were based on a previous, Phase III, open‐label, randomized study of comparison between pembrolizumab and chemotherapy for treatment‐naïve PD‐L1 expressor with unresectable advanced or metastatic NSCLC (KEYNOTE‐042).19